Cipher Pharmaceuticals, Inc. (CPH.TO)
13.65
0.00 (0.00%)
CAD |
TSX |
Oct 09, 16:00
Cipher Pharmaceuticals Enterprise Value : 334.51M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 334.51M |
| October 08, 2026 | 334.51M |
| October 07, 2026 | 334.76M |
| October 06, 2026 | 339.85M |
| October 05, 2026 | 335.78M |
| October 02, 2026 | 334.51M |
| October 01, 2026 | 334.51M |
| September 30, 2026 | 334.51M |
| September 29, 2026 | 335.53M |
| September 28, 2026 | 334.51M |
| September 25, 2026 | 340.61M |
| September 24, 2026 | 344.93M |
| September 23, 2026 | 350.27M |
| September 22, 2026 | 356.87M |
| September 21, 2026 | 354.08M |
| September 18, 2026 | 360.43M |
| September 17, 2026 | 365.26M |
| September 16, 2026 | 356.37M |
| September 15, 2026 | 357.64M |
| September 14, 2026 | 362.97M |
| September 11, 2026 | 351.03M |
| September 10, 2026 | 348.49M |
| September 09, 2026 | 349.50M |
| September 08, 2026 | 347.22M |
| September 04, 2026 | 352.05M |
| Date | Value |
|---|---|
| September 03, 2026 | 353.32M |
| September 02, 2026 | 357.13M |
| September 01, 2026 | 348.23M |
| August 31, 2026 | 335.27M |
| August 28, 2026 | 342.13M |
| August 27, 2026 | 347.47M |
| August 26, 2026 | 345.95M |
| August 25, 2026 | 347.47M |
| August 24, 2026 | 345.95M |
| August 21, 2026 | 345.95M |
| August 20, 2026 | 351.54M |
| August 19, 2026 | 352.55M |
| August 18, 2026 | 351.28M |
| August 17, 2026 | 351.28M |
| August 14, 2026 | 346.96M |
| August 13, 2026 | 343.15M |
| August 12, 2026 | 346.20M |
| August 11, 2026 | 443.79M |
| August 10, 2026 | 434.14M |
| August 07, 2026 | 433.63M |
| August 06, 2026 | 438.71M |
| August 05, 2026 | 417.62M |
| August 04, 2026 | 421.43M |
| July 31, 2026 | 415.33M |
| July 30, 2026 | 405.93M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 167.86M |
| Bausch Health Cos., Inc. | 31.48B |
| BioSyent, Inc. | 188.68M |
| Revive Therapeutics Ltd. | 10.94M |
| Knight Therapeutics, Inc. | 988.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.556M |
| Revenue (Quarterly) | 16.71M |
| Total Expenses (Quarterly) | 11.15M |
| EPS Diluted (Quarterly) | 0.2138 |
| Gross Profit Margin (Quarterly) | 65.58% |
| Profit Margin (Quarterly) | 33.26% |
| Earnings Yield | 11.36% |
| Operating Earnings Yield | 7.54% |
| Normalized Earnings Yield | 11.36 |